GlobalData on MSN21h
MSD commences Phase III trial of DLBCL treatmentMSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...
MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate's ...
Co., Inc. (NYSE:MRK), recently acquired 15,000 shares of the company's common stock. The transaction, which took place on ...
Co., Inc. (NYSE:MRK), recently purchased 2,832.861 shares of the company's common stock. The acquisition, valued at approximately $249,999, was completed at a price of $88.25 per share. Following this ...
Pharmaceutical Technology on MSN20h
Genentech eyes lupus market for Gazyva with positive Phase III data readoutGenentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...
Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...
News Medical on MSN22h
How lymphoid tissues protect against viral infectionsResearchers explore the cellular and molecular adaptations associated with human secondary lymphoid tissue in adults during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback